Case Studies

BACKGROUND: At the request of the CFO, LifeSci Advisors started working with CinCor a few months prior to their $200M IPO on Jan 6th, 2022. LIFESCI’s ACTIVITIES Pre-IPO:  LifeSci performed the following activities which brought investors into the stock and ultimately led to a successful equity offering: Advised on messaging and changes to investor presentation…

BACKGROUND Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. LifeSci Advisors has been engaged to support Bellus Health with investor…

Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of PharmaMar’s product Zepzelca® (lurbinectedin) in 2020 by partner Jazz Pharmaceuticals as a second-line treatment for SCLC, the Zepzelca® story struggled to gain traction with investors and the broader PharmaMar investment…

In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.  …

BACKGROUND AlphaTau has been a LifeSci client since July 2021. As part of a strategy to raise visibility amongst investors, LifeSci organized over 60 virtual and in-person Non-Deal Roadshows since joining forces as well as hosting an in-person High-Net-Worth Group Event with over 73 meeting attendees. LIFESCI’S ACTIVITIES • Continuous proactive outreach to new investors,…